ClinicalTrials.gg
RecruitingNCT05273762Updated Oct 1, 2026

Treatment of Low-Risk Submassive Pulmonary Embolism With FlowTriever

An interventional study of FlowTriever in Pulmonary Embolism, sponsored by Northwell Health. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Northwell Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 9 months later.
Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Planned enrollment
135th of 166
30 · median 142
Started
2022
with 8 others
No phase
82 of 236
17 open now
Primary completion
2027-07
later than 22 of 42 live
Registered
183rd of 236
by date

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 135th largest by planned enrollment of the 166 interventional ones that give a count, is one of 9 that started in 2022, is one of 82 with no phase, reaches primary completion later than 22 of the 42 other live ones, and was the 183rd registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

This study is focused on investigating the efficacy and safety of the FlowTriever device to treat low-risk submassive pulmonary embolism.

Read the detailed description

In this study, patients that present with low-risk submassive pulmonary embolism with hemodynamic stability and with either positivity of cardiac biomarkers, or radiographic or echocardiographic evidence of right ventricular strain will be assigned to be treated with mechanical thrombectomy, which includes conscious sedation, via FlowTriever.

03

Conditions studied

  • Pulmonary Embolism

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I1. ≥ 18 years of age

I2. Clinical signs and symptoms of low-risk Intermediate pulmonary embolism defined per 2019 ESC Guidelines:

Only one of the following:

  • Presence of either RV strain or RV dilation on CT scan or Echo TTE
  • 4th generation Troponin T > 0.01 ng/mL or 5th generation Troponin T >14 ng/L

Troponin I > 51.4 ng/L (Northwell reference laboratory)

I3. sPESI score 0 or >1*

*Signs of RV dysfunction on Echo TTE or CTPA or elevated cardiac biomarker levels may be present, despite a calculation of sPESI 0.

I4. Echocardiogram, Computed Tomography Pulmonary Angiogram, or pulmonary angiographic evidence of proximal filing defect in at least one main, lobar, or segmental pulmonary artery with or without pulmonary infarction

I5. Hemodynamically stable

Exclusion criteria

EXCLUSION CRITERIA

E1. Patients with active and severe COVID-19 infection (e.g. using ventilator, requiring hemodynamic support)

E2. Unable to anti-coagulate with heparin or alternative

E3. Known sensitivity to radiographic contrast agents that cannot be pre-treated

E4. \< 6 months

E5. Current participation in another study that may interfere with the patient's participation in this study.

E6. Inability to consent

E7. Patient is pregnant or plans to become pregnant within the next 6 months and/or currently breastfeeding.

E8. Subsegmental pulmonary embolism only

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    FlowTriever

    Device: FlowTriever

Interventions

  • DeviceFlowTriever

    Mechanical thrombectomy for pulmonary embolism

06

What researchers measure

Primary outcomes

  1. Change in mMRC dyspnea score from

    Time frame: Baseline (state at time of admission to hospital) to 30-day follow-up.

Secondary outcomes

  1. Change in Pulmonary Embolism Quality of Life Questionnaire (PEmbQOL)

    Time frame: Procedure to 30-day, 3-month, and 6-month follow up.

  2. Change in Six Minute Walk Test (6MWT) (distance covered in meters over 6 minutes)

    Time frame: Pre-procedure to 30-day, 3-month, and 6-month follow up.

  3. Echocardiogram Measurements: Change

    Time frame: Pre-procedure to 30-day and 6-month follow up

  4. Echocardiogram Measurements: Change

    Time frame: From pre-procedure echocardiogram compared to 30-day and compared to 6-month follow up

  5. ICU Length of Stay

    Time spent in the Intensive Care Unit (ICU) for the length of the hospital visit.

    Time frame: Length of index hospitalization, length of hospitalization median of 9.1 days, length of ICU stay median 3.1 per JNS

  6. Hospital Duration

    Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal

  7. Device related death Device related bleeding Device related vascular injury Device related cardiac injury Clinical deterioration Rescue intervention

    Time frame: From end of index hospitalization to 30 days post-procedure, whichever comes first

  8. Change in hemodynamic measurements

    Time frame: Before insertion of device during the procedure compared to 5 minutes after device is removed

  9. Site Complications

    Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal

  10. Oxygen Requirement

    Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal

  11. All-cause Mortality

    Time frame: Length of index hospitalization, length median of 9.1 days per AHA journal

  12. Bleeding Re-thrombosis Edema Pain

    Time frame: From end of index hospitalization to 30 days post-procedure, whichever comes first

07

Study locations

2 of 2 sites recruiting
  • Northern Westchester Hospital
    Mount Kisco, New York 10549, United States
    Enrolling by invitation
  • Lenox Hill Hospital
    New York, New York 10075, United States
    Recruiting
    • Victoria Roselli · Contactvroselli@northwell.edu
    • Bushra Mina, MD · Principal investigator
    • Chad Kliger, MD · Sub investigator
    • Craig Basman, MD · Sub investigator
    • Biana Trost, MD · Sub investigator
    • Arber Kodra, MD · Sub investigator
    • Miguel Alvarez Villela, MD · Sub investigator
    • Zein Kattih, MD · Sub investigator
    • Jonathan Moore, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jul 2027, 65 months after the start.

Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 65 months is above that.

Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Jul 2024 → Jul 2027 and completion Jul 2024 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Mar 10, 2022
StartActual
Jan 25, 2022
Primary completionEst.
Jul 1, 2027was Jul 2024
CompletionEst.
Jul 25, 2027was Jul 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 1, 2024→Jul 1, 2027
Oct 1, 2026
Study completion
Jul 25, 2024→Jul 25, 2027
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Jul 1, 2024→Jul 1, 2027
    Study completion Jul 25, 2024→Jul 25, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05273762
Lead sponsor
Northwell Health
Collaborators
Inari Medical
Responsible party
Sponsor
First posted
Mar 10, 2022
Start date
Jan 25, 2022
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 25, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Victoria Roselli, Clinical Research Coordinator
Contact
vroselli@northwell.edu
212-434-3695

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion